| Size | Price | Stock | Qty |
|---|---|---|---|
| 50g |
|
||
| Other Sizes |
| Targets |
Cyjohnphos does not have a specific primary biological target, as it functions primarily as a ligand for transition metal catalysts rather than a direct pharmacological agent. The mechanism by which this compound exerts its biological activity involves coordination with metal centers to form stable complexes that facilitate catalytic reactions or inhibit specific enzymatic processes. In the context of catalysis, the compound's bulky and electron-rich structure enhances the reactivity and selectivity of palladium and nickel catalysts in cross-coupling reactions. Its ability to form stable complexes with metal ions may also influence its interactions with metalloenzymes and other metal-dependent biological processes. However, the compound is not intended for direct therapeutic use.
|
|---|---|
| ln Vitro |
In vitro, Cyjohnphos is used in palladium-catalyzed amination of aryl halides and triflates and in Suzuki-Miyaura coupling reactions. It is used in combination with a nickel catalyst for the Suzuki-Miyaura arylation of tertiary benzylic acetates with aryl boroxines to produce diaryl and triaryl quaternary stereocenters. The compound is a ligand for triflate and aryl halide amination in Buchwald-Hartwig amination reactions. It is a biochemical reagent that can be used as a biological material or organic compound for life science related research. In organic synthesis, it serves as a valuable ligand for various transition metal-catalyzed reactions, enhancing reaction rates and selectivity. Its bulky structure allows for the stabilization of reactive intermediates and the prevention of catalyst decomposition.
|
| ln Vivo |
In vivo studies are not performed with Cyjohnphos, as it is a chemical catalyst ligand rather than a pharmacological agent. The compound is not intended for administration to living organisms. Its use in catalysis means that it is handled as a chemical reagent in laboratory settings, and comprehensive in vivo studies on the parent compound are not documented.
|
| Enzyme Assay |
Cell-free assays for catalytic reactions involving Cyjohnphos involve mixing the compound (2-5 mol%) with a palladium or nickel catalyst, an aryl halide, a coupling partner, and a base in a solvent, and heating at 80-120°C for 12-24 hours under an inert atmosphere. The reaction progress is monitored by GC or HPLC. The compound's ability to enhance catalytic activity and selectivity can be assessed by comparing reaction yields and enantiomeric excess. Its use in Buchwald-Hartwig amination involves standard protocols for palladium-catalyzed C-N bond formation. The compound's coordination with metal centers can be studied using various analytical techniques, including NMR spectroscopy and X-ray crystallography.
|
| Cell Assay |
Cellular assays are not performed with Cyjohnphos due to its role as a catalyst ligand. The compound is not used as a test article in cell-based experiments because of its potential to cause non-specific effects due to its metal-coordinating properties. Instead, the compound is used in the synthesis of drug candidates that are subsequently tested in cellular assays. However, the parent compound itself is not used in cellular assays.
|
| Animal Protocol |
Animal studies are not conducted with Cyjohnphos. The compound is a chemical reagent and is not intended for administration to animals. Toxicity and pharmacological profiles for the parent compound are inferred from related phosphine ligands, as specific studies on the parent compound are not documented. The compound is not administered to animals in research settings.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Cyjohnphos are not available. As a lipophilic phosphine with a molecular weight of 350.48 g/mol, it is expected to have limited bioavailability and is not intended for systemic exposure. Comprehensive pharmacokinetic studies have not been performed, as the compound is not intended for therapeutic use. For research purposes, the compound is typically handled as a neat chemical and not administered to living organisms for pharmacokinetic profiling.
|
| Toxicity/Toxicokinetics |
Toxicological data for Cyjohnphos are limited. Standard safety precautions for handling phosphines apply, including the use of personal protective equipment such as gloves and safety goggles. The compound should be handled in a well-ventilated area, and contact with skin and eyes should be avoided. In case of exposure, affected areas should be rinsed thoroughly with water. The compound should be stored under inert atmosphere to prevent oxidation. The compound is not classified as a carcinogen or mutagen based on available data, but comprehensive toxicological evaluation has not been performed. As with all research chemicals, it should be handled with care and used only in accordance with safety guidelines.
|
| Additional Infomation |
Cyjohnphos is a research chemical, not an approved drug. It has no clinical trial or marketing approval status for therapeutic use. The compound is an air-stable, bulky, electron-rich monodentate biarylphosphine ligand developed by the Buchwald group. It is used in palladium-catalyzed amination of aryl halides and triflates and in Suzuki-Miyaura coupling reactions. It is used in combination with a nickel catalyst for the Suzuki-Miyaura arylation of tertiary benzylic acetates with aryl boroxines to produce diaryl and triaryl quaternary stereocenters. The compound is a ligand for triflate and aryl halide amination in Buchwald-Hartwig amination reactions. It is a biochemical reagent that can be used as a biological material or organic compound for life science related research. It is supplied with a purity of ≥97% and should be stored under inert atmosphere.
|
| Molecular Formula |
C24H31P
|
|---|---|
| Molecular Weight |
350.48
|
| Exact Mass |
350.216
|
| CAS # |
247940-06-3
|
| PubChem CID |
2734216
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
499.5±24.0 °C at 760 mmHg
|
| Melting Point |
102-106 °C(lit.)
|
| Flash Point |
271.7±29.2 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| LogP |
8.45
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
0
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
356
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1(CCCCC1)P(C2=C(C=CC=C2)C3=CC=CC=C3)C4CCCCC4
|
| InChi Key |
LCSNDSFWVKMJCT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H31P/c1-4-12-20(13-5-1)23-18-10-11-19-24(23)25(21-14-6-2-7-15-21)22-16-8-3-9-17-22/h1,4-5,10-13,18-19,21-22H,2-3,6-9,14-17H2
|
| Chemical Name |
dicyclohexyl-(2-phenylphenyl)phosphane
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8532 mL | 14.2661 mL | 28.5323 mL | |
| 5 mM | 0.5706 mL | 2.8532 mL | 5.7065 mL | |
| 10 mM | 0.2853 mL | 1.4266 mL | 2.8532 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
